K. Gauger

发表

Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer

Manfred Schmitt, Nadia Harbeck, Marion Kiechle, 2004, Thrombosis and Haemostasis.

Study participation improves treatment strategies and individual patient care in participating centers.

M. Kiechle, N. Harbeck, H. Sommer, 2006, Anticancer research.

C‐Met overexpression in node‐positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu

E. Lengyel, G. V. Vande Woude, N. Harbeck, 2005, International journal of cancer.

History of HER2/neu and development of trastuzumab

N. Harbeck, K. Gauger, A. Willems, 2009 .

Participation in study improves treatment strategies and individual patient care in the participating centres

M. Kiechle, N. Harbeck, H. Sommer, 2005 .

P70 The ADEBAR-trial — participation in a randomized phase III study (evaluating the role of adjuvant docetaxel in high-risk breast cancer patients) improves treatment strategies and individual patient care in recruiting centers

M. Kiechle, N. Harbeck, H. Sommer, 2005 .

Antibody therapy for breast cancer.

N. Harbeck, K. Gauger, A. Willems, 2005, Anticancer research.

Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.

J. Foekens, M. Look, M. Kiechle, 2004, Clinical breast cancer.

Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR-Study

M. Kiechle, N. Harbeck, H. Sommer, 2005 .

Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer

M. Kiechle, N. Harbeck, V. Magdolen, 2004, Thrombosis and Haemostasis.